Rivulet Media (RIVU) 10-K 8 Jan 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2015	Dec. 29, 2015	Mar. 31, 2015
Document And Entity Information
Entity Registrant Name	Bio-Matrix Scientific Group, Inc.
Entity Central Index Key	1,079,282
Document Type	10-K
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 1,980,106
Entity Common Stock, Shares Outstanding		4,889,075,005
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Sep. 30, 2014
CURRENT ASSETS
Cash	$ 76,355	$ 502
Prepaid Expenses	25,000	15,000
Note Receivable	12,051	10,422
Interest Receivable	1,381	233
Total Current Assets	114,787	26,157
OTHER ASSETS
Deposits	4,200	4,200
Available for Sale Securities	159,720	3,000
Total Other Assets	163,920	7,200
TOTAL ASSETS	278,707	33,357
CURRENT LIABILITIES
Accounts Payable	167,977	158,492
Notes Payable	400,336	379,233
Bank Overdraft	0	6,137
Accrued Payroll	738,095	587,094
Accrued Payroll Taxes	44,485	51,117
Accrued Interest	324,750	271,495
Accrued Rent	10,000	0
Accrued Expenses	5,000	5,000
Convertible Note Payable Net of Unamortized Discount	231,507	97,701
Due to Affiliate	0	0
Current portion, note payable to affiliated party	1,000	1,000
Total Current Liabilities	1,923,150	1,557,269
Total Liabilities	1,923,150	1,557,269
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock ($0.0001 par value) 20,000,000 shares authorized; 2,063,821 issued and outstanding as of September 30, 2015 and September 30, 2014	207	207
Series AA Preferred ($0.0001 par value) 100,000 shares authorized; 94,852 issued and outstanding as of September 30, 2015 and September 30, 2014	9	9
Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of September 30, 2015 and September 30, 2014	4	4
Series B Preferred Shares ($0.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of September 30, 2015 and September 30, 2014 respectively	73	73
Common Stock ($0.0001 par value) 5,000,000,000 shares authorized; 4,232,931,345 and 3,079,900,942 issued and outstanding as of September 30, 2015 and September 30, 2014 respectively	423,292	307,989
Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of September 30, 2015 and September 30, 2014	0	0
Additional Paid in capital	29,004,809	16,510,439
Contributed Capital	509,355	509,355
Retained Earnings (Deficit)	9,704,398	22,461,356
Accumulated Other Comprehensive Income (Loss)	(41,368,641)	(41,333,361)
Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc.	(1,726,494)	(1,543,929)
Noncontrolling Interest in subsidiary	82,050	20,017
Total Stockholders' Equity	(1,644,444)	(1,523,912)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 278,707	$ 33,357

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Sep. 30, 2014$ / sharesshares
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	20,000,000
Preferred stock, shares issued	2,063,821
Preferred stock, shares outstanding	2,063,821
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Common stock, shares authorized	5,000,000,000
Common stock, shares issued	3,079,900,942
Common stock, shares outstanding	3,079,900,942
Series AA
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	100,000
Preferred stock, shares issued	94,852
Preferred stock, shares outstanding	94,852
Series AAA
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	1,000,000
Preferred stock, shares issued	40,000
Preferred stock, shares outstanding	40,000

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
REVENUES	$ 192,000	$ 0
COST AND EXPENSES
Research and Development	282,295	23,867
General and Administrative	1,430,553	599,234
Consulting and Professional Fees	587,470	246,214
Rent	58,071	0
Total Costs and Expenses	2,358,389	869,315
OPERATING LOSS	(2,166,389)	(869,315)
OTHER INCOME & (EXPENSES)
Interest Income	1,148	233
Interest Expense	(56,063)	(35,136)
Loss on Settlement of Debt through Equity Issuance	(942,015)	(1,112,230)
Loss on Settlement of Debt through issuance of Common Shares of Regen Biopharma, Inc. below fair value	(9,191,857)	0
Interest Expense attributable to amortization of discount	(150,806)	0
Expense Related to issuance of Convertible Debt to Star City	(247,500)	0
Preferred Shares of Regen Biopharma, Inc. pursuant to contractual obligations	(3,475)	0
Other Income	0	490
Other Expense	0	(65,000)
Total Other Income & (Expense)	(10,590,568)	(1,211,643)
NET INCOME (LOSS)	(12,756,958)	(2,080,958)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	8,977,733	226,234
NET INCOME (LOSS) available to common shareholders	$ (3,779,225)	$ (1,854,724)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.001)	$ (0.001)
Weighted average number of shares outstanding	2,855,088,489	2,865,048,153

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net Income (Loss)	$ (12,756,958)	$ (2,080,958)
Add: Unrealized Gains on Securities
Less: Unrealized Losses on Securities
Total Other Comprehensive Income (Loss)	$ (35,280)	$ (4,000)
Comprehensive Income	$ (12,792,238)	$ (2,084,958)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)	$ (12,756,958)	$ (2,080,958)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Stock issued by licensee to subsidiary in payment of services	$ (192,000)
Stock issued for services rendered by consultants		$ 26,180
Stock issued for interest		3,570
Stock issued for expenses		$ 48,000
Interest Expense attributable to amortization of discount	$ 150,806
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses	(10,000)
Increase (Decrease) in Accounts Payable	9,484	$ 19,920
Increase (Decrease) in Accrued Expenses	207,624	12,397
Increase (Decrease) in bank Overdraft	(6,137)	6,137
(Increase) Decrease in Interest Receivable	$ (1,148)	(233)
Increase (Decrease) in Due to Affiliate		(34,895)
(Increase) Decrease in Note Receivable	$ (1,629)	(10,422)
Net Cash Provided by (Used in) Operating Activities	$ (12,599,958)	(2,010,304)
CASH FLOWS FROM FINANCING ACTIVITIES
Preferred Stock issued for Cash		$ 100,000
Common Stock issued for Cash
Common Stock issued for Debt
Common Stock issued for Accrued Salaries
Preferred Stock issued for Accrued Salaries
Common Stock issued pursuant to Contractual Obligations
Additional paid in Capital	$ 1,010,650	$ 300,000
Increase (Decrease) in due to shareholder	0
Stock in subsidiary sold for cash	$ 50,000
Principal borrowings (repayments) on notes and Convertible Debentures
Convertible Debentures	$ 208,603	$ 316,862
Principal borrowings (repayments) on Convertible Debentures	$ 1,272,686
(Increase) Decrease in Deferred Financing Costs		$ 65,000
Loss on Settlement of Debt through Equity Issuance	$ 10,133,872	1,112,230
Net Cash Provided by (Used in) Financing Activities	12,675,811	1,894,092
Net Increase (Decrease) in Cash	75,853	(116,212)
Cash at Beginning of Period	502	502
Cash at End of Period	76,355	502
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	157,500	$ 158,000
Common Shares of Regen Biopharma, Inc. Issued for Debt	1,002,686
Cash paid for Interest	0	$ 0
Cash paid for Income tax	$ 0	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Series AAA	Series B Preferred Stock	Series AAA Preferred Stock	Preferred Stock	Common Stock	Nonvoting Convertible Preferred Stock	Additional Paid-In Capital	Retained Earnings	Deficit Attributable to noncontrolling interest	Noncontrolling Interest	Contributed Capital	Accumulated Other Comprehensive Income (Loss)	Total
Beginning balance, Shares at Sep. 30, 2013	94,852	725,409	40,000	2,063,821	2,390,304,145	0
Beginning balance, Amount at Sep. 30, 2013	$ 9	$ 73	$ 4	$ 207	$ 239,029	$ 0	$ 14,845,671	$ 24,542,314		$ 5,765	$ 509,355	$ (41,329,361)	$ (1,186,934)
Common Shares issued for debt, Shares					120,000,000
Common Shares issued for debt, Amount					$ 12,000		32,500						44,500
Common Stock issued to Consultant, Shares					200,000
Common Stock issued to Consultant, Amount					$ 20		360						380
Common Shares issued for debt (B), Shares					120,000
Common Shares issued for debt (B), Amount					$ 12,000								12,000
Common Shares issued for debt (C), Shares					150,000,000
Common Shares issued for debt (C), Amount					$ 15,000								15,000
Common Shares issued to vendor, Shares					30,000,000
Common Shares issued to vendor, Amount							45,000						48,000
Common stock of subsidiary issued for Cash, Amount							100,000						100,000
Common stock of subsidiary issued for Cash (B), Amount							100,000						100,000
Common stock of subsidiary issued for Cash (C), Amount							100,000						100,000
Loss recognized on issuance of shares for less than fair value							648,500						648,500
Accumulated Other Comprehensive Income (Loss)												(4,000)	(4,000)
Noncontrolling interest recognized							(6,597)			6,597			0
Net Income (loss)								(920,888)					(920,888)
Ending balance, Shares at Dec. 31, 2013	94,852	725,409	40,000	2,063,821	2,810,504,145	0
Ending balance, Amount at Dec. 31, 2013	$ 9	$ 73	$ 4	$ 207	$ 281,049	$ 0	15,865,434	23,621,426	$ 0	12,362	509,355	(41,333,361)	(1,043,442)
Common Shares issued for debt, Shares					140,000,000
Common Shares issued for debt, Amount					$ 14,000		70						14,070
Common Shares issued for debt (B), Shares					500,000
Common Shares issued for debt (B), Amount					$ 50		950						1,000
Loss recognized on issuance of shares for less than fair value							336,230						336,230
Accumulated Other Comprehensive Income (Loss)												8,000	8,000
Noncontrolling interest recognized							(82,664)			82,664			0
Net Income (loss)								(529,555)					(529,555)
Ending balance, Shares at Mar. 31, 2014	94,852	725,409	40,000	2,063,821	2,951,004,145	0
Ending balance, Amount at Mar. 31, 2014	$ 9	$ 73	$ 4	$ 207	$ 295,099	$ 0	16,120,020	23,091,871	0	95,026	509,355	(41,325,361)	1,213,696
Accumulated Other Comprehensive Income (Loss)												(6,000)	(6,000)
Noncontrolling interest recognized							47,466			(47,466)			0
Net Income (loss)								(246,447)					(246,447)
Ending balance, Shares at Jun. 30, 2014	94,852	725,409	40,000	2,063,821	2,951,004,145	0
Ending balance, Amount at Jun. 30, 2014	$ 9	$ 73	$ 4	$ 207	$ 295,099	$ 0	16,167,486	22,845,424	0	47,560	509,355	(41,331,361)	(1,466,144)
Common Shares issued for cash, Shares					45,000,000
Common Shares issued for cash, Amount					$ 45,000		95,500						100,000
Common Shares issued for debt, Shares					37,500,000
Common Shares issued for debt, Amount					$ 3,750		33,750						37,500
Common Stock issued to Consultant, Shares					8,896,797
Common Stock issued to Consultant, Amount					$ 890		24,910						25,800
Common Shares issued for debt (B), Shares					37,500,000
Common Shares issued for debt (B), Amount					$ 3,750		33,750						37,500
Loss recognized on issuance of shares for less than fair value							127,500						127,500
Accumulated Other Comprehensive Income (Loss)												(2,000)	(2,000)
Noncontrolling interest recognized							27,543			(27,543)			0
Net Income (loss)								(384,068)					(384,068)
Ending balance, Shares at Sep. 30, 2014	94,852	725,409	40,000	2,063,821	3,079,900,942	0
Ending balance, Amount at Sep. 30, 2014	$ 9	$ 73	$ 4	$ 207	$ 307,989	$ 0	16,510,439	22,461,356	0	20,017	509,355	(41,333,361)	(1,523,912)
Common Shares issued for debt, Shares					100,000,000
Common Shares issued for debt, Amount					$ 10,000		27,500						37,500
Common Shares issued for debt (B), Shares					100,000,000
Common Shares issued for debt (B), Amount					$ 10,000		25,000						35,000
Common Shares issued for debt (C), Shares					200,000
Common Shares issued for debt (C), Amount					$ 20,000								20,000
Common Shares issued for debt (D), Shares					100,000,000
Common Shares issued for debt (D), Amount					$ 10,000								10,000
Common Shares issued for debt (E), Shares					150,000,000
Common Shares issued for debt (E), Amount					$ 15,000								15,000
Sale of owned and issued shares of Regen Biopharma, Inc.							50,000						50,000
Shares of subsidiary issed to consultant							22,440						22,440
Loss recognized on issuance of shares for less than fair value							587,500						587,500
Accumulated Other Comprehensive Income (Loss)												(2,000)	(2,000)
Noncontrolling interest recognized							55,786			(55,786)			0
Net Income (loss)								(856,892)					(856,892)
Ending balance, Shares at Dec. 31, 2014	94,852	725,409	40,000	2,063,821	3,729,900,942	0
Ending balance, Amount at Dec. 31, 2014	$ 9	$ 73	$ 4	$ 207	$ 372,989	$ 0	17,278,665	21,604,464		(35,786)	509,355	(41,335,361)	(1,605,363)
Common Shares issued for debt, Shares					103,030,303
Common Shares issued for debt, Amount					$ 10,303		6,697						17,000
Common Shares issued for debt (B), Shares					200,000,000
Common Shares issued for debt (B), Amount					$ 20,000								20,000
Common stock of subsidiary issued for services, Amount							140,000						140,000
Common stock of subsidiary issued for services (B), Amount							63,739						63,739
Common stock of subsidiary issued for Debt, Amount							558,575						558,575
Common stock of subsidiary issued for Debt (B), Amount							175,000						175,000
Common stock of subsidiary issued for Debt (C), Amount							50,000						50,000
Common stock of subsidiary issued for Debt (D), Amount							100,000						100,000
Preferred Shares of subsidiary issued for Purchase of Patent							100						100
Preferred Shares of subsidiary issued pursuant to contractual obligations							3,154						3,154
Preferred Shares of subsidiary issued to Consultants for Services							420						420
Sale of owned and issued shares of Regen Biopharma, Inc.							20,000						20,000
Recognition of beneficial conversion feature, convertible note							300,000						300,000
Loss recognized on issuance of shares for less than fair value							8,393,947						8,393,947
Accumulated Other Comprehensive Income (Loss)												1,000	1,000
Noncontrolling interest recognized							(467,943)			467,943			0
Regen Restricted Stock Award compensation expense recognized							132,602						132,602
Net Income (loss)								(9,344,958)					(9,344,958)
Ending balance, Shares at Mar. 31, 2015	94,852	725,409	40,000	2,063,821	4,032,931,245	0
Ending balance, Amount at Mar. 31, 2015	$ 9	$ 73	$ 4	$ 207	$ 403,292	$ 0	26,754,956	12,259,506		432,174	509,355	(41,334,361)	(974,784)
Common Shares issued for debt, Shares					200,000,000
Common Shares issued for debt, Amount					$ 20,000								20,000
Common stock of subsidiary issued for Debt, Amount							40,000						40,000
Common stock of subsidiary issued for Debt (B), Amount							15,000						15,000
Common stock of subsidiary issued for Debt (C), Amount							15,000						15,000
Common stock of subsidiary issued for Debt (D), Amount							50,000						50,000
Preferred Shares of subsidiary issued pursuant to contractual obligations							143						143
Preferred Shares of subsidiary issued to Consultants for Services							20						20
Loss recognized on issuance of shares for less than fair value							1,077,425						1,077,425
Noncontrolling interest recognized							216,981			(216,981)			0
Net Income (loss)								(1,829,173)					(1,829,173)
Ending balance, Shares at Jun. 30, 2015		725,409	40,000	2,063,821	4,232,931,245	0
Ending balance, Amount at Jun. 30, 2015		$ 73	$ 4	$ 207	$ 423,292	$ 0	28,417,291	10,430,333	$ 215,193	215,193	509,355	(41,333,361)	(1,337,603)
Common stock of subsidiary issued for Cash, Amount							33,333						33,333
Common stock of subsidiary issued for Cash (B), Amount							16,667						16,667
Common stock of subsidiary issued for services, Amount							61,836						61,836
Common stock of subsidiary issued for services (B), Amount							19,941						19,941
Loss recognized on issuance of shares for less than fair value							75,000						75,000
Accumulated Other Comprehensive Income (Loss)												(35,280)	(35,280)
Noncontrolling interest recognized							133,143			(133,143)			0
Regen Restricted Stock Award compensation expense recognized							$ 247,588						247,588
Net Income (loss)								(725,935)					(725,935)
Ending balance, Shares at Sep. 30, 2015		725,409	40,000	2,063,821	4,232,931,245	0	29,004,809
Ending balance, Amount at Sep. 30, 2015		$ 73	$ 4	$ 207	$ 423,292	$ 0	$ 29,004,809	$ 9,704,398		$ 82,050	$ 509,355	$ (41,368,641)	$ (1,644,443)

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Bio-Matrix Scientific Group, Inc. (“Company”) was organized October 6, 1998, under the laws of the State of Delaware as Tasco International, Inc. From October 6, 1998 to June 3, 2006 its activities have been limited to capital formation, organization, and development of its business plan to provide production of visual content and other digital media, including still media, 360-degree images, video, animation and audio for the Internet. On July 3, 2006 the Company abandoned its efforts in the field of digital media production when it acquired 100% of the share capital of Bio-Matrix Scientific Group, Inc., a Nevada corporation, (“BMSG”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by John Lauring. As a result of this transaction, the former stockholder of BMSG held approximately 80% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by BMSG under the purchase method of accounting, and was treated as a recapitalization with BMSG as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to August 2, 2005 (date of inception), of the reverse acquisition completed on July 3, 2006, and represent the operations of BMSG. Through its controlled subsidiary, Regen BioPharma, Inc., the Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials The Company holds 18.3% of the equity and 70% of the voting power of Regen BioPharma, Inc. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and controlled subsidiary (Regen) and Entest BioMedical, Inc., (“Entest”), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011. Significant inter-company transactions have been eliminated. C. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates. D. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. E. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized. F. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments as of September 30, 2015 consisted of Securities Available for Sale consisting of 8066667 shares of Entest Biomedical, Inc and a Note Receivable from Entest Biomedical, Inc. for $12,051 . The fair value of Securities Available for sale as of September 30, 2015 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company. The fair value of the Note Receivable was valued according to Level 3 input. G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share. I. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the quarter ended September 30, 2015 and the year ended September 30, 2014 respectively.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Sep. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2 RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows. In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Options and Warrants

Options and Warrants	12 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Options and Warrants	NOTE 3. OPTIONS AND WARRANTS As of September 30, 2015 the Company has no options or warrants outstanding.

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 4. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Exclusive of a onetime non-cash gain of $41,645,688 recognized upon the deconsolidation of Entest Biomedical, Inc., the Company generated net losses of $31,277,641 excluding $663,649 of Equity in Net Losses of Entest Biomedical, Inc. recognized) during the period from August 2, 2005 (inception) through September 30, 2015. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. During the quarter ended March 31, 2015 Regen Biopharma Inc. raised $775,000 through the issuance of convertible debt. During the quarter ended June 30, 2015 Regen Biopharma Inc. raised $90,000 through the issuance of convertible debt. During the quarter ended September 30, 2015 Regen Biopharma, Inc. raised $50,000 through the issuance of 333,333 units of securities of Regen Biopharma, Inc. (“Units”) with each Unit consisting of 2 common shares and one share of Regen Biopharma, Inc.’s Series A Preferred Stock .

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 5. INCOME TAXES As of September 30, 2015 Deferred tax assets: Net operating tax carry forwards $ 10,647,527 Other -0- Gross deferred tax assets 10,647,527 Valuation allowance (10,647,527 Net deferred tax assets $ -0- As of September 30, 2015 the Company has a Deferred Tax Asset of 10,647,527 completely attributable to net operating loss carry forwards of approximately $31,316,257 ( which expire 20 years from the date the loss was incurred) consisting of (a) $38,616, of Net Operating Loss Carry forwards acquired in the reverse acquisition of BMSG and (b) $31,277,641 attributable to Bio-Matrix Scientific Group, Inc. a Delaware corporation, BMSG and Regen. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. In addition, the reverse acquisition of BMSG has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0. Income tax is calculated at the 34% Federal Corporate Rate.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 6. RELATED PARTY TRANSACTIONS As of September 30, 2015 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $141,286. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum. As of September 30, 2015 Regen is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $50. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to Regen by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month, As of September 30, 2015 Entest Biomedical, Inc. is indebted to Regen in the amount of $12,051. $12,051lent by Regen to Entest Biomedical, Inc . is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. On June 23, 2015 Regen Biopharma, Inc. entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby Regen Biopharma, Inc. granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen Biopharma, Inc. (“ License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is a wholly owned subsidiary of Entest Biomedical, Inc. Pursuant to the Agreement, Zander shall pay to Regen Biopharma, Inc. one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on the first anniversary of the effective date of the Agreement and each subsequent anniversary. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander or in common stock of Entest BioMedical Inc. valued as of the lowest closing price on the principal exchange upon which said common stock trades publicly within the 14 trading days prior to issuance. Pursuant to the Agreement, Zander shall pay to Regen Biopharma, Inc. royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay Regen Biopharma, Inc. ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen Biopharma, Inc. receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to Regen Biopharma, Inc. minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by Regen Biopharma, Inc.: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to Regen Biopharma, Inc. with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to Regen Biopharma, Inc. with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On September 28, 2015 Zander caused to be issued to Regen Biopharma, Inc. 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to Regen Biopharma, Inc. by Zander as a license initiation fee. David R. Koos serves as sole officer and director of both Zander and Entest Biomedical, Inc. and also serves as Chairman and Chief Executive Officer of Regen Biopharma, Inc..

Notes Payable and Convertible N

Notes Payable and Convertible Notes Payable	12 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes Payable	NOTE 7. NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE September 30, 2014 Bio Technology Partners Business Trust (Company) 35,000 David R. Koos ( Company)( Note 6) 189,065 David R. Koos ( Regen)( Note 6) 30,168 The Sherman family Trust 125,000 Total $ 379,233 September 30, 2015 Bio Technology Partners Business Trust (Company) 14,000 Bio Technology Partners Business Trust (Regen) 84,000 David R. Koos ( Company)( Note 6) 141,286 David R. Koos ( Regen)( Note 6) 50 The Sherman family Trust 2,000 Bostonia Partners ( Company) 40,000 Bostonia Partners ( Regen) 119,000 Total $ 400,336 Amounts due to the Biotechnology Partners Business Trust. are due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. These amount was loaned pursuant to a Line of Credit Promissory Note issued by Regen in the maximum amount of $500,000 or so much thereof as may be disbursed to, or for the benefit of the Borrower by Lender in Lender's sole and absolute discretion and pursuant to a Line of Credit Promissory Note issued by the Company in the maximum amount of $700,000 or so much thereof as may be disbursed to, or for the benefit of the Borrower by Lender in Lender's sole and absolute discretion. All loans to the Company and Regen made by David R. Koos are due and payable at the demand of Koos and bear simple interest at a rate of 15% per annum. These amount was loaned pursuant to a Line of Credit Promissory Note issued by Regen in the maximum amount of $700,000 or so much thereof as may be disbursed to, or for the benefit of the Borrower by Lender in Lender's sole and absolute discretion and pursuant to a Line of Credit Promissory Note issued by the Company in the maximum amount of $700,000 or so much thereof as may be disbursed to, or for the benefit of the Borrower by Lender in Lender's sole and absolute discretion. All amounts due to the Sherman Family Trust bear no interest and are due and payable, in whole or in part, at the option of the holder. These amount was loaned pursuant to a Line of Credit Promissory Note issued by the Company in the maximum amount of $700,000 or so much thereof as may be disbursed to, or for the benefit of the Borrower by Lender in Lender's sole and absolute discretion. $60,000 lent to Regen Biopharma, Inc. by Bostonia Partners is due and payable September 16, 2016 and bear simple interest at a rate of 10% per annum $59,000 lent to Regen Biopharma, Inc. by Bostonia Partners is due and payable September 22, 2016 and bear simple interest at a rate of 10% per annum. $40,000 lent to the Company by Bostonia Partners is due and payable September 2, 2016 and bear simple interest at a rate of 10% per annum. As of September 30, 2015 the weighted average interest rate on all debt due and payable in one year or less was 11.7% As of September 30, 2014 the weighted average interest rate on all debt due and payable in one year or less was 9.5% CONVERTIBLE NOTES PAYABLE SEPTEMBER 30, 2015 $ 50,000 Scott Levine $ 10,000 Mike and Ofie Weiner $ 18,400 Mike and Ofie Weiner $ 2,301 Bio Technology Partners Business Trust $ 300,000 Star City Capital, LLC $ 380,701 Total $300,000 due and payable to Starcity Capital LLC (“Note”) bears no interest, is payable on April1, 2016 and permits conversion at the Holder’s option into common shares of the Company under the following terms and conditions: The Holder of the Note is entitled, at its option, at any time after 180 days after March 27, 2015 to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to the greater of (iii) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (iv) $0.0001. Upon : (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) then, in each case, Holder may convert the unpaid principal amount of this Note into shares of Common Stock immediately prior to such event at the Conversion Price. other than as provided in (i), (ii) and(ii) above, the Holder shall not have the right to convert its debt into shares which, when added to such Holder’s other holdings in the Company stock, shall have caused such Holder to hold more than 9.99% of the Company’s outstanding common stock. The issuance of the Note amounted in a beneficial conversion feature of $300,000 which is amortized under the Interest Method over the life of the Note. The amount by which the instrument’s as converted value exceeds the principal amount as of September 30, 2015 is $245,454. $50,000 due and payable to Scott Levine bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on November 14, 2009. No demand for payment has been made. $10,000 due and payable to Mike and Ofie Weiner bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on March 3 , 2010. No demand for payment has been made. $18,400 due and payable to Mike and Ofie Weiner bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on December 28, 2009. No demand for payment has been made. $2,301 due and payable to Bio Technology Partners Business Trust bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on November 26, 2009. No demand for payment has been made. As of September 30, 2014 the unamortized discount on convertible notes outstanding is $0. As of September 30, 2015 the unamortized discount on convertible notes outstanding is $ 149,193. CONVERTIBLE NOTES ISSUED BY REGEN BIOPHARMA, INC. During the quarter ended March 31, 2015 Regen Biopharma, Inc. issued Convertible Notes ( “Notes”) with an aggregate face value of $882,686 . Consideration for these Notes consisted of: (a) $775,000 cash and (b) Satisfaction of $107,686 of existing indebtedness: Each Note becomes due and payable at the demand of the Lender at any time after one year subsequent to the issuance date and bears simple interest at 10% per annum payable quarterly at the demand of the Lender. All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender. Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shale remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by Regen Biopharma, Inc. by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period. If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series “A” Stock of Regen Biopharma, Inc. for each share of Common Stock received through conversion. All Notes were fully converted during the quarter ended March 31, 2015. 31,539,262 common shares of Regen were issued to the Convertible Noteholders in satisfaction of the convertible indebtedness. 31,538,862 of Regen Biopharma, Inc.’s Series A Preferred shares were issued to Noteholders pursuant to the terms and conditions of the Notes. Regen Biopharma, Inc. analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in Regen Biopharma, Inc.’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. Regen Biopharma, Inc. values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $2,368,685 was recognized by Regen Biopharma, Inc.. This liability was eliminated prior to the end of Regen Biopharma, Inc.’s second quarter as a result of the full conversion of all Notes prior to the end of Regen Biopharma, Inc.’s second quarter. During the quarter ended June 30, 2015 the Regen Biopharma, Inc. issued Convertible Notes ( “Notes”) with an aggregate face value of $90,000 . Consideration for these Notes consisted of $90,000. All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Or (2) $0.03 per share Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender. Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shall remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by the Company by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period. If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series “A” Stock of the Company for each share of Common Stock received through conversion. During the quarter ended June 30, 2015 the Regen issued 3,214,285 of its common shares in satisfaction of the abovementioned convertible notes and 3,214,285 shares of its Series A Preferred stock in accordance with the terms and conditions of abovementioned convertible notes. Regen Biopharma, Inc. analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in Regen Biopharma, Inc.’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. Regen values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $350,666 was recognized by the Company in connection with $90,000 of convertible notes payable issued during the quarter ended June 30, 2015. This liability was eliminated prior to the end of Regen’s third quarter as a result of the full conversion of these convertible noted prior to the end of Regen’s third quarter.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9. COMMITMENTS AND CONTINGENCIES On April 12, 2013 a complaint (Complaint) was filed in the U.S. District Court Southern District of the State of new York against the Company, the Company’s Chairman and Does 1-50 by Star city Capital, LLC (“Plaintiff”) alleging securities fraud, common law fraud, negligent misrepresentation, breach of fiduciary duties and breach of contract in connection with the issuance of. The Plaintiff is also request declaratory relief from the Court. The action arises from the issuance and subsequent cancellation of 103,030,303 of the company’s common shares in satisfaction of $17,000 of convertible indebtedness of the Company held by the Plaintiff. The Plaintiff alleges that a cancellation notice sent by them to the Company’s transfer agent was meant to instruct the Transfer Agent simply to cancel the physical certificate in order that an equivalent number of shares may be transferred via DWAC to the Plaintiff’s stockbroker for the benefit of the Plaintiff. DWAC is the acronym for Deposit/Withdrawal At Custodian. The DWAC transaction system run by The Depository Trust Company (a.k.a. DTC or CEDE & CO) permits brokers and custodial banks, the DTC participants, to request the movement of shares to or from the issuer’s transfer agent electronically. A DWAC results in the crediting or debiting of shares to or from DTC’s book-entry account on the records of the issuer maintained by the transfer agent. The Company believes that the cancellation notice sent by the Plaintiff clearly represents a cancellation of the conversion notice itself. The convertible indebtedness held by the Plaintiff was convertible at Holder’s demand into the common shares of the Company’s stock at a conversion price per share equal to 55% (the “Discount”) of the lowest closing bid price for the Company’s common stock during the 5 trading days immediately preceding a conversion date, as reported by Bloomberg (the “Closing Bid Price”); provided that if the closing bid price for the common stock on the date in which the conversion shares are deposited into Holder’s brokerage account and confirmation has been received that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase price for the conversion shares would be adjusted such that the Discount shall be taken from the closing bid price on the Clearing Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price(“Reset”). The Company and the Plaintiff had agreed on a limitation on conversion equal to 9.99% of the Company’s outstanding common stock. On February 2, 2015 Plaintiff and the Company entered into a Settlement Agreement and Mutual General Release to fully and finally resolve the aforementioned legal action pursuant to the following terms and conditions: (a) Within seven business days of the Company’s transfer agent’s receipt of an appropriate opinion of counsel, the Company shall deliver to Starcity or its designee or assignee (which designation or assignment shall be provided in writing) via DWAC, 103,030,303 of the common shares of the Company , it being the agreement of the parties that such issuance shall constitute full and complete satisfaction of $17,000 due to Starcity by the Company. (b) The Company shall deliver to Starcity a non interest bearing Convertible Note in the face amount of $300,000 (“Note”) due and payable April 1, 2016. The Holder of this Note is entitled, at its option, at any time after 180 days after the date that consideration of $52,500 is paid to the Company to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to the greater of (i) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (ii) $0.0001. Other than as provided in 5(p) of the Note ), the Holder shall not have the right to convert its debt into shares which, when added to such Holder’s other holdings in the Company stock, shall have caused such Holder to hold more than to hold more than 9.99% of the Company's outstanding common stock. Section 5(p) of the Note states that: Upon : (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) then, in each case, Holder may convert the unpaid principal amount of this Note into shares of Common Stock immediately prior to such event at the Conversion Price. In the event that Starcity fails to fund the Note by making a payment of $52,500 to the Company on or before April 1, 2015, the Company’s obligations under this Note shall be terminated, cancelled and relinquished. On August 21, 2012 the Company entered into a settlement funding agreement with Princeton Research, Inc. and Jan Vandersande (collectively the “PRI Parties”) which obligates the Company to pay the PRI Parties $1,000 a month over thirty months. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to Regen Biopharma, Inc. by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of Regen and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month. On March 20, 2015 Regen Biopharma, Inc. agreed to sublease 199 square feet of laboratory space located at 5310 Eastgate Mall, San Diego, CA 92121 from Human BioMolecular Research Institute (“Sublease Agreement”). Pursuant to the terms of the Sublease Agreement Regen Biopharma, Inc. will pay rent of $400 per month to Human BioMolecular Research Institute (“HBRI”) . The term of the sublease shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. Regen Biopharma, Inc. terminated its sublease with Human BioMolecular Research Institute On March 20, 2015 Regen Biopharma, Inc entered into a Research Agreement with HBRI wherein HBRI agreed to provide a variety of professional, scientific and technical services for the proper conduct of research by Regen Biopharma, Inc. and also to make available certain research equipment to Regen Biopharma, Inc. The term of the agreement shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. As consideration Regen Biopharma, Inc shall pay a monthly fee of $2,700 to HBRI over the term of the agreement. Regen Biopharma, Inc. terminated the aforementioned agreement with Human BioMolecular Research Institute

Investment Securities

Investment Securities	12 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Investment Securities	NOTE 10. INVESTMENT SECURITIES As of the quarter ending September 30, 2012 the Company reclassified 66,667 ( retroactively adjusted for reverse stock split.) common shares of Entest Biomedical, Inc. as Securities Available for Sale from Securities Accounted for under the Equity Method. On September 28, 2015 Zander Theraputics, Inc. caused to be issued to Regen Biopharma, Inc. 8,000,000 of the common shares of Entest Biomedical, Inc in satisfaction of one hundred thousand US dollars ($100,000) to be paid to Regen Biopharma, Inc. by Zander Theraputics, Inc as a license initiation fee. The common shares of Entest Biomedical, Inc described above constitute the Company’s sole investment securities.

Stock Transactions

Stock Transactions	12 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Stock Transactions	NOTE 12. STOCK TRANSACTIONS On October 14, 2013 the Company Issued 120,000,000 Common Shares in satisfaction of $ 44,500 of indebtedness. On November 4. 2013 the Company Issued 200,000 Common Shares as consideration for services rendered. On November 13, 2013 the Company Issued 120,000,000 Common Shares in satisfaction of $ 12,000 of indebtedness. On December 5, 2013 the Company issued 150,000,000 Common Shares in satisfaction of $15,000 of indebtedness. On December 12, 2013 the Company issued 30,000,000 of its common shares to a vendor in settlement of a dispute over fees owed between the vendor and Regen. On October 16, 2013 Regen issued 100,000 of its common shares for consideration consisting of $100,000. On November 15, 2013 Regen issued 100,000 of its common shares for consideration consisting of $100,000. On December 12, 2013 Regen issued 100,000 of its common shares for consideration consisting of $100,000. On January 23, 2014 the Company Issued 140,000,000 Common Shares in satisfaction of $ 14,070 of indebtedness. On January 28, 2014 the Company Issued 500,000 Common Shares in satisfaction of $ 1,000 of convertible indebtedness. On July 1, 2014 the Company issued 45,000,000 common shares for cash consideration of $100,000. On August 12, 2014 the Company issued 8,896,797 common shares with a fair value at the time of issuance of $25,800 as consideration to a consultant On August 18, 2014 the Company Issued 37,500,000 Common Shares in satisfaction of $ 37,500 of indebtedness. On August 26, 2014 the Company Issued 37,500,000 Common Shares in satisfaction of $ 37,500 of indebtedness.

Property Dividend

Property Dividend	12 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Property Dividend	NOTE 13. PROPERTY DIVIDEND On March 25, 2014 the Company paid a property dividend of 20,000,000 common shares of Regen Biopharma, Inc. to its shareholders. This dividend was distributed pro rata to all common and preferred shareholders of record as of March 18, 2014.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 14. SUBSEQUENT EVENTS On October 1, 2014 the Company Issued 100,000,000 Common Shares in satisfaction of $ 37,500 of indebtedness. On October 9, 2014 the Company Issued 100,000,000 Common Shares in satisfaction of $35,000 of indebtedness. On October 31, 2014 the Company Issued 200,000,000 Common Shares in satisfaction of $20,000 of indebtedness. On December 9, 2014 the Company Issued 100,000,000 Common Shares in satisfaction of $10,000 of indebtedness.

Organization and Summary of S20

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
A. BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
B. PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and controlled subsidiary (Regen) and Entest BioMedical, Inc., (“Entest”), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011. Significant inter-company transactions have been eliminated.
C. USE OF ESTIMATES	C. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates.
D. CASH EQUIVALENTS	D. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
E. PROPERTY AND EQUIPMENT	E. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
F. FAIR VALUE OF FINANCIAL INSTRUMENTS	F. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments as of September 30, 2015 consisted of Securities Available for Sale consisting of 8066667 shares of Entest Biomedical, Inc and a Note Receivable from Entest Biomedical, Inc. for $12,051 . The fair value of Securities Available for sale as of September 30, 2015 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company. The fair value of the Note Receivable was valued according to Level 3 input.
G. INCOME TAXES	G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
H. BASIC EARNINGS (LOSS) PER SHARE	H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share.
I. ADVERTISING	I. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the quarter ended September 30, 2015 and the year ended September 30, 2014 respectively.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Deferred tax assets	As of September 30, 2015 Deferred tax assets: Net operating tax carry forwards $ 10,647,527 Other -0- Gross deferred tax assets 10,647,527 Valuation allowance (10,647,527 Net deferred tax assets $ -0-

Notes Payable and Convertible22

Notes Payable and Convertible Notes Payable (Tables)	12 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	September 30, 2014 Bio Technology Partners Business Trust (Company) 35,000 David R. Koos ( Company)( Note 6) 189,065 David R. Koos ( Regen)( Note 6) 30,168 The Sherman family Trust 125,000 Total $ 379,233 September 30, 2015 Bio Technology Partners Business Trust (Company) 14,000 Bio Technology Partners Business Trust (Regen) 84,000 David R. Koos ( Company)( Note 6) 141,286 David R. Koos ( Regen)( Note 6) 50 The Sherman family Trust 2,000 Bostonia Partners ( Company) 40,000 Bostonia Partners ( Regen) 119,000 Total $ 400,336
Convertible Notes Payable	$ 50,000 Scott Levine $ 10,000 Mike and Ofie Weiner $ 18,400 Mike and Ofie Weiner $ 2,301 Bio Technology Partners Business Trust $ 300,000 Star City Capital, LLC $ 380,701 Total

Organization and Summary of S23

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Apr. 01, 2016	Jul. 03, 2006
Accounting Policies [Abstract]
Acquired share capital of Bio-Maxtrix Scientific Gruop, Inc.				100.00%
Consideration of shares of common stock of the Company				10,000,000
Cancelation of shares of the Company owned and held by John Lauring				10,000,000
Percent of voting capital stock of the Company held by former stockholder of BMSG				80.00%
Equity in Regen BioPharma, Inc.	18.30%
Voting power of Regen BioPharma, Inc.	70.00%
Shares of Entest BioMedical, Inc. for Securities Available for Sale	8,066,667
Note Receivable from Entest Biomedical, Inc.			$ 52,500
Valuation allowance	100.00%
Advertising expenses	$ 0	$ 0

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended			12 Months Ended	110 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Non-cash gain upon deconsolidation ofEntest Biomedical, Inc.					$ 41,645,688
Net Losses					31,277,641
Equity in Net Losses of Entest Biomedical, Inc.					$ 663,649
Net borrowings				$ 116,861
Issuance of convetible debt by Regen Biopharma Inc.; Value		$ 90,000	$ 775,000
Stock issued during period, shares	333,333
Stock issued during period, value	$ 50,000

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (Details)	Sep. 30, 2015USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 10,647,527
Other	0
Gross deferred tax assets	10,647,527
Valuation allowance	(10,647,527)
Net deferred tax assets	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Sep. 30, 2015USD ($)
Income Tax Disclosure [Abstract]
Deferred tax asset	$ 10,647,527
Net operating loss carry forwards	31,316,257
Amount of NOL acuired in reverse aquisition fo BMSG	38,616
Amount of NOL attributable to Bio-Matrix Scientific Group, Inc, BMSG and Regen.	$ 31,277,641
Federal Corporate income tax Rate	34.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 28, 2015
License fee	$ 100,000
Royalties, receivable	$ 10,000
Royalties receivable, percentage	4.00%
Stock received as license initiian fee, shares		8,000,000
Stock received as license initiation fee, value		$ 100,000
David R. Koos
Interest rate of note receivable	15.00%
Notes payable to related party	$ 141,286
Regen, David R. Koos
Interest rate of note receivable	15.00%
Notes payable to related party	$ 50
Regen
Interest rate of note receivable	10.00%
Notes payable to related party	$ 12,051

Notes Payable and Convertible28

Notes Payable and Convertible Notes Payable - Notes Payable (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Notes Payable	$ 400,336
Bio Technology Partners Business Trust (Company)
Notes Payable	14,000	$ 35,000
David R. Koos (Company)
Notes Payable	141,286	189,065
David R. Koos (Regen)
Notes Payable	50	30,168
The Sherman Family Trust
Notes Payable	2,000	$ 125,000
Bio Technology Partners Business Trust (Regen)
Notes Payable	84,000
Bostonia Partners (Company)
Notes Payable	40,000
Bostonia Partners (Regen)
Notes Payable	$ 119,000

Notes Payable and Convertible29

Notes Payable and Convertible Notes Payable - Convertible Notes Payable (Details) - USD ($)	Apr. 01, 2016	Sep. 30, 2015
Debt Disclosure [Abstract]
Scott Levine		$ 50,000
Mike and Ofie Weiner		10,000
Mike and Ofie Weiner		18,400
Bio Technology Partners Business Trust		2,301
StarCity Capital LLC	$ 300,000	300,000
Total		$ 380,701

Notes Payable and Convertible30

Notes Payable and Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2015	Apr. 01, 2016	Sep. 30, 2014
Interest rate on notes payable			11.70%		9.50%
Note receivable				$ 52,500
Unamortized discount			$ 149,193
Convertible notes issued			$ 300,000	$ 300,000
Regen
Convertible note		$ 882,686
Convertible note issued for cash		775,000
Convertible note issued for idebtedness		$ 107,686
Convertible note, interest rate		10.00%
Aggregate derivative liability	$ 350,666	$ 2,368,685
Convertible notes issued	$ 90,000
Regen | Series AAA
Stock issued	3,214,285	31,538,862
Regen | Common Stock
Stock issued		31,539,262
Regen | Common Stock
Stock issued	3,214,285
The Sherman Family Trust
Interest rate on notes payable			0.00%
Line of credit			$ 700,000
Bio Technology Partners Business Trust
Interest rate on notes payable			10.00%
Line of credit			$ 500,000
David Koos
Interest rate on notes payable			15.00%
Line of credit			$ 700,000
Due Sept. 16, 2016
Interest rate on notes payable			10.00%
Note receivable			$ 60,000
Due Sept. 22, 2016
Interest rate on notes payable			10.00%
Note receivable			$ 59,000
Bostonia Partners
Related party note payable			$ 40,000
Interest rate on notes payable			10.00%
Star City Capital LLC
Related party note payable			$ 300,000
Conversion terms			(iii) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (iv) $0.0001. Upon : (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) then, in each case, Holder may convert the unpaid principal amount of this Note into shares of Common Stock immediately prior to such event at the Conversion Price. other than as provided in (i), (ii) and(ii) above, the Holder shall not have the right to convert its debt into shares which, when added to such Holder’s other holdings in the Company stock, shall have caused such Holder to hold more than 9.99% of the Company’s outstanding common stock.
Conversion price			$ .0001
Amount by which the instrument ecxeeds the principal amount			$ 245,454
Scott Levine
Related party note payable			$ 50,000
Interest rate on notes payable			12.00%
Due Mar. 3, 2010
Interest rate on notes payable			12.00%
Line of credit			$ 10,000
Conversion price			$ 0.15
Due Dec. 28, 2009 | Mike and Ofie Weiner
Interest rate on notes payable			12.00%
Line of credit			$ 18,400
Conversion price			$ 0.15
Due Nov. 26, 2009
Interest rate on notes payable			12.00%
Line of credit			$ 2,301
Conversion price			$ 0.15

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - $ / shares	Sep. 30, 2015	Sep. 30, 2014
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	20,000,000	20,000,000
Preferred stock; shares issued	2,063,821	2,063,821
Preferred stock; shares outstanding	2,063,821	2,063,821
Common stock; par value	$ 0.0001	$ 0.0001
Common Stock; shares authorized	5,000,000,000	5,000,000,000
Common stock; shares issued	4,232,931,345	3,079,900,942
Common stock; shares outstanding	4,232,931,345	3,079,900,942
Series AAA
Preferred stock; par value	$ 0.0001
Preferred stock; shares authorized	1,000,000
Preferred stock; shares issued	40,000
Preferred stock; shares outstanding	40,000
Non Voting Preferred Stock
Preferred stock; par value	$ 1
Preferred stock; shares authorized	200,000
Preferred stock; shares issued	0
Preferred stock; shares outstanding	0
Series AA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized		100,000
Preferred stock; shares issued	94,852	94,852
Preferred stock; shares outstanding	94,852	94,852
Series B Preferred Stock
Preferred stock; par value	$ .0001
Preferred stock; shares issued	725,409
Preferred stock; shares outstanding	725,409

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Feb. 09, 2015USD ($)	Aug. 31, 2012USD ($)	Sep. 30, 2015USD ($)ft²	Sep. 30, 2015USD ($)ft²	Apr. 01, 2016USD ($)	Feb. 02, 2015shares	Apr. 12, 2013USD ($)shares
Cancellation of company common shares held by Plaintiff | shares							103,030,303
Satisfaction of convertible indebtedness held by Plaintiff							$ 17,000
Limitation on conversion of outstanding common stock							9.99%
Common shares deliverable to Star City | shares						103,030,303
Satisfaction agreement amount	$ 17,000	$ 1,000
Convertible note amount			$ 300,000	$ 300,000	$ 300,000
Convertible note terms	The Holder of this Note is entitled, at its option, at any time after 180 days after the date that consideration of $52,500 is paid to the Company to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to the greater of (i) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (ii) $0.0001.
Note receivable from Star City					$ 52,500
Office Space
Rental space | ft²			2,300
Monthly Fee			$ 5,000
Laboratory Space
Rental space | ft²				199
Monthly Fee				$ 400
Research Agreement
Monthly Fee				$ 2,700

Investment Securities (Details

Investment Securities (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2012	Sep. 28, 2015
Accounting Policies [Abstract]
Common shares reclassified	66,667
Stock issued as license fee, shares		8,000,000
Stock issued as license fee, value		$ 100,000

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Mar. 17, 2015
Stock issued for services, value		$ 26,180
Stock issued in satisfaction of indebtedness, shares	1,153,030,303
Stock issued in satisfaction of indebtedness, value	$ 174,500
Regen
Stock issued for cash, shares	666,666
Stock issued for cash, value	$ 33,333
Stock issued for services, shares	1,425,808
Stock issued for services, value	$ 307,956
Stock issued as Restricted Stock Awards	25,000,000
Stock issued in satisfaction of indebtedness, shares	35,753,547
Stock issued in satisfaction of indebtedness, value	$ 1,003,575
Regen | Series AAA
Stock issued for cash, shares	333,333
Stock issued for cash, value	$ 16,667
Stock issued for services, shares	4,500,000
Stock issued as Restricted Stock Awards	10,000,000
Stock dividend	10,395,217
Stock dividend terms	Common shareholders received one share of Series A Preferred Stock for every 10 shares of Regen Biopharma, Inc. common Stock owned as of the Record Date.
Stock issued convertible note	34,753,547
Stock issued for patents			$ 1,000,000

Property Dividend (Details Narr

Property Dividend (Details Narrative)	1 Months Ended
	Mar. 31, 2014shares
Notes to Financial Statements
Regen common stock issued to shareholders	20,000,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Dec. 29, 2015	Dec. 15, 2015	Nov. 20, 2015	Nov. 13, 2015	Oct. 28, 2015	Oct. 02, 2015	Sep. 30, 2014
Common stock issued for debt, Shares			273,476,806				3,862,657,778
Common stock issued for debt, Amount			$ 30,082				$ 63,138
Common stock, Par value	$ 0.0001							$ 0.0001
Common stock, authorized	5,000,000,000							5,000,000,000
Preferred stock, par value	$ 0.0001							$ 0.0001
Preferred stock, authorized	20,000,000							20,000,000
Regen
Stock issued for cash, shares		4,000,000		2,200,000		3,333,334
Stock issued for cash, value		$ 100,000		$ 55,000		$ 166,666
Common Stock
Common stock, Par value					$ 0.0001
Common stock, authorized					8,000,000,000
Preferred stock, par value					$ 0.0001
Preferred stock, authorized					20,000,000
Non Voting Preferred Stock
Preferred stock, par value	$ 1
Preferred stock, authorized	200,000
Convertible stock conversion features	Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.
Series AAA
Stock issued for cash, shares		4,000,000		2,200,000
Stock issued for cash, value		$ 100,000		$ 55,000
Stock issued during period for services, shares				400,000
Series AAA | Regen
Stock issued for cash, shares						1,666,667
Stock issued for cash, value						$ 83,333
Stock issued per employment agreement, shares						11,000,000